Global Dry Eye Drugs

Dry Eye Drugs Comprehensive Study by Type (Artificial Tears, Anti-inflammatory Drugs), Application (Hospital Pharmacies, Drug Stores, Online Pharmacies), Treatment (Topical Cyclosporine A Eye Drops, Lifitegrast, Artificial Teardrops and Ointments, Temporary Punctal Occlusion, Permanent Punctal Occlusion, Autologous Serum Drops), Dosage Form (Eye Drops, Eye Solutions) Players and Region - Global Market Outlook to 2028

Dry Eye Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Dry Eye Drugs Market Scope
The dry eye drug market is expected to grow in the future due to the increased number of cases of dry eye disease resulting in the increased demand for its treatment. Additionally, factors such as aging, direct contact with dry wind or smoke and lack of vitamin A, etc increase the occurrence of dry eye more likely which is boosting the demand for dry eye drugs. Further, market players are focusing on clinical trials for new drugs. For example, the FDA has accepted a new drug application for Kala Pharmaceuticals’ KPI-121 0.25% for the temporary relief of dry eye signs and symptoms.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAllergan plc (Ireland), Novartis International AG (Switzerland), Bausch Health Companies Inc. (Canada), Santen Pharmaceutical Co., Ltd. (Japan), Shire Plc (United States), Johnson & Johnson (United States), United Laboratories, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India) and Senju Pharmaceutical Co. Ltd. (Japan)
CAGR%


The key manufacturers are targeting the innovations of the products with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions to maintain their presence in the market Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Dry Eye Drugs market throughout the predicted period.

Allergan plc (Ireland), Novartis International AG (Switzerland), Bausch Health Companies Inc. (Canada), Santen Pharmaceutical Co., Ltd. (Japan), Shire Plc (United States), Johnson & Johnson (United States), United Laboratories, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India) and Senju Pharmaceutical Co. Ltd. (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Chongqing Jianfeng Industrial Group Co., Ltd (China) and Kala Pharmaceuticals (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Dry Eye Drugs market by Type , by Application (Hospital Pharmacies, Drug Stores and Online Pharmacies) and Region with country level break-up.

On the basis of geography, the market of Dry Eye Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In October 2023, Novartis launched Iluvien (fluocinolone acetonide implant) for the treatment of moderate to severe dry eye disease. Iluvien is a small, sustained-release implant that is placed in the eye to provide long-term relief from dry eye symptoms.
In September 2023, Alcon and AbbVie announced a collaboration to develop and commercialize AbbVie's late-stage dry eye drug lifitegrast (Xiidra). This partnership brings together Alcon's leading position in eye care with AbbVie's expertise in developing and commercializing innovative pharmaceuticals.
The FDA has accepted a new drug application for Kala Pharmaceuticals’ KPI-121 0.25% for the temporary relief of dry eye signs and symptoms, the company announced in a press release.

Influencing Trend:
Increasing Research and Development Activities from both Public and Private Research Organizations for New Drugs

Market Growth Drivers:
Increase in the Prevalence of Dry Eye Syndrome, A Rising Awareness of Eye Care and Increase in Awareness among the Population about Dry Eye Disease

Challenges:
the Long Approval Process that For Approvement in any Drug

Restraints:
Straight Government Regulation associated with Drug Production

Opportunities:
Potential Growth From Emerging Countries and Increasing Number of Pipelines Studies and Drug Development

Key Target Audience
Dry Eye Drugs Manufacturers, Dry Eye Drugs Distributors/Traders/Wholesalers, Dry Eye Drugs Subcomponent Manufacturers, Industry Association, Healthcare Industry, Potential Investors, Research and Development Firm and Downstream Vendors

Report Objectives / Segmentation Covered

By Type
  • Artificial Tears
  • Anti-inflammatory Drugs
By Application
  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
By Treatment
  • Topical Cyclosporine A Eye Drops
  • Lifitegrast
  • Artificial Teardrops and Ointments
  • Temporary Punctal Occlusion
  • Permanent Punctal Occlusion
  • Autologous Serum Drops

By Dosage Form
  • Eye Drops
  • Eye Solutions

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence of Dry Eye Syndrome
      • 3.2.2. A Rising Awareness of Eye Care
      • 3.2.3. Increase in Awareness among the Population about Dry Eye Disease
    • 3.3. Market Challenges
      • 3.3.1. The Long Approval Process that For Approvement in any Drug
    • 3.4. Market Trends
      • 3.4.1. Increasing Research and Development Activities from both Public and Private Research Organizations for New Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dry Eye Drugs, by Type, Application, Treatment, Dosage Form and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dry Eye Drugs (Value)
      • 5.2.1. Global Dry Eye Drugs by: Type (Value)
        • 5.2.1.1. Artificial Tears
        • 5.2.1.2. Anti-inflammatory Drugs
      • 5.2.2. Global Dry Eye Drugs by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Drug Stores
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Dry Eye Drugs by: Treatment (Value)
        • 5.2.3.1. Topical Cyclosporine A Eye Drops
        • 5.2.3.2. Lifitegrast
        • 5.2.3.3. Artificial Teardrops and Ointments
        • 5.2.3.4. Temporary Punctal Occlusion
        • 5.2.3.5. Permanent Punctal Occlusion
        • 5.2.3.6. Autologous Serum Drops
      • 5.2.4. Global Dry Eye Drugs by: Dosage Form (Value)
        • 5.2.4.1. Eye Drops
        • 5.2.4.2. Eye Solutions
      • 5.2.5. Global Dry Eye Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Dry Eye Drugs (Volume)
      • 5.3.1. Global Dry Eye Drugs by: Type (Volume)
        • 5.3.1.1. Artificial Tears
        • 5.3.1.2. Anti-inflammatory Drugs
      • 5.3.2. Global Dry Eye Drugs by: Application (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Drug Stores
        • 5.3.2.3. Online Pharmacies
      • 5.3.3. Global Dry Eye Drugs by: Treatment (Volume)
        • 5.3.3.1. Topical Cyclosporine A Eye Drops
        • 5.3.3.2. Lifitegrast
        • 5.3.3.3. Artificial Teardrops and Ointments
        • 5.3.3.4. Temporary Punctal Occlusion
        • 5.3.3.5. Permanent Punctal Occlusion
        • 5.3.3.6. Autologous Serum Drops
      • 5.3.4. Global Dry Eye Drugs by: Dosage Form (Volume)
        • 5.3.4.1. Eye Drops
        • 5.3.4.2. Eye Solutions
      • 5.3.5. Global Dry Eye Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Dry Eye Drugs (Price)
      • 5.4.1. Global Dry Eye Drugs by: Type (Price)
  • 6. Dry Eye Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bausch Health Companies Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Santen Pharmaceutical Co., Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shire Plc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. United Laboratories, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Senju Pharmaceutical Co. Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Dry Eye Drugs Sale, by Type, Application, Treatment, Dosage Form and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dry Eye Drugs (Value)
      • 7.2.1. Global Dry Eye Drugs by: Type (Value)
        • 7.2.1.1. Artificial Tears
        • 7.2.1.2. Anti-inflammatory Drugs
      • 7.2.2. Global Dry Eye Drugs by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Drug Stores
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Dry Eye Drugs by: Treatment (Value)
        • 7.2.3.1. Topical Cyclosporine A Eye Drops
        • 7.2.3.2. Lifitegrast
        • 7.2.3.3. Artificial Teardrops and Ointments
        • 7.2.3.4. Temporary Punctal Occlusion
        • 7.2.3.5. Permanent Punctal Occlusion
        • 7.2.3.6. Autologous Serum Drops
      • 7.2.4. Global Dry Eye Drugs by: Dosage Form (Value)
        • 7.2.4.1. Eye Drops
        • 7.2.4.2. Eye Solutions
      • 7.2.5. Global Dry Eye Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Dry Eye Drugs (Volume)
      • 7.3.1. Global Dry Eye Drugs by: Type (Volume)
        • 7.3.1.1. Artificial Tears
        • 7.3.1.2. Anti-inflammatory Drugs
      • 7.3.2. Global Dry Eye Drugs by: Application (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Drug Stores
        • 7.3.2.3. Online Pharmacies
      • 7.3.3. Global Dry Eye Drugs by: Treatment (Volume)
        • 7.3.3.1. Topical Cyclosporine A Eye Drops
        • 7.3.3.2. Lifitegrast
        • 7.3.3.3. Artificial Teardrops and Ointments
        • 7.3.3.4. Temporary Punctal Occlusion
        • 7.3.3.5. Permanent Punctal Occlusion
        • 7.3.3.6. Autologous Serum Drops
      • 7.3.4. Global Dry Eye Drugs by: Dosage Form (Volume)
        • 7.3.4.1. Eye Drops
        • 7.3.4.2. Eye Solutions
      • 7.3.5. Global Dry Eye Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Dry Eye Drugs (Price)
      • 7.4.1. Global Dry Eye Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dry Eye Drugs: by Type(USD Million)
  • Table 2. Dry Eye Drugs Artificial Tears , by Region USD Million (2017-2022)
  • Table 3. Dry Eye Drugs Anti-inflammatory Drugs , by Region USD Million (2017-2022)
  • Table 4. Dry Eye Drugs: by Application(USD Million)
  • Table 5. Dry Eye Drugs Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 6. Dry Eye Drugs Drug Stores , by Region USD Million (2017-2022)
  • Table 7. Dry Eye Drugs Online Pharmacies , by Region USD Million (2017-2022)
  • Table 8. Dry Eye Drugs: by Treatment(USD Million)
  • Table 9. Dry Eye Drugs Topical Cyclosporine A Eye Drops , by Region USD Million (2017-2022)
  • Table 10. Dry Eye Drugs Lifitegrast , by Region USD Million (2017-2022)
  • Table 11. Dry Eye Drugs Artificial Teardrops and Ointments , by Region USD Million (2017-2022)
  • Table 12. Dry Eye Drugs Temporary Punctal Occlusion , by Region USD Million (2017-2022)
  • Table 13. Dry Eye Drugs Permanent Punctal Occlusion , by Region USD Million (2017-2022)
  • Table 14. Dry Eye Drugs Autologous Serum Drops , by Region USD Million (2017-2022)
  • Table 15. Dry Eye Drugs: by Dosage Form(USD Million)
  • Table 16. Dry Eye Drugs Eye Drops , by Region USD Million (2017-2022)
  • Table 17. Dry Eye Drugs Eye Solutions , by Region USD Million (2017-2022)
  • Table 18. South America Dry Eye Drugs, by Country USD Million (2017-2022)
  • Table 19. South America Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 20. South America Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 21. South America Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 22. South America Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 23. Brazil Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 24. Brazil Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 25. Brazil Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 26. Brazil Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 27. Argentina Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 28. Argentina Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 29. Argentina Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 30. Argentina Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 31. Rest of South America Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 32. Rest of South America Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 33. Rest of South America Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 34. Rest of South America Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 35. Asia Pacific Dry Eye Drugs, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 37. Asia Pacific Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 38. Asia Pacific Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 39. Asia Pacific Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 40. China Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 41. China Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 42. China Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 43. China Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 44. Japan Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 45. Japan Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 46. Japan Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 47. Japan Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 48. India Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 49. India Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 50. India Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 51. India Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 52. South Korea Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 53. South Korea Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 54. South Korea Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 55. South Korea Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 56. Taiwan Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 57. Taiwan Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 58. Taiwan Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 59. Taiwan Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 60. Australia Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 61. Australia Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 62. Australia Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 63. Australia Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 68. Europe Dry Eye Drugs, by Country USD Million (2017-2022)
  • Table 69. Europe Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 70. Europe Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 71. Europe Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 72. Europe Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 73. Germany Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 74. Germany Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 75. Germany Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 76. Germany Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 77. France Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 78. France Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 79. France Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 80. France Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 81. Italy Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 82. Italy Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 83. Italy Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 84. Italy Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 85. United Kingdom Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 86. United Kingdom Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 87. United Kingdom Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 88. United Kingdom Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 89. Netherlands Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 90. Netherlands Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 91. Netherlands Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 92. Netherlands Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 93. Rest of Europe Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 94. Rest of Europe Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 95. Rest of Europe Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 96. Rest of Europe Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 97. MEA Dry Eye Drugs, by Country USD Million (2017-2022)
  • Table 98. MEA Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 99. MEA Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 100. MEA Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 101. MEA Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 102. Middle East Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 103. Middle East Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 104. Middle East Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 105. Middle East Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 106. Africa Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 107. Africa Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 108. Africa Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 109. Africa Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 110. North America Dry Eye Drugs, by Country USD Million (2017-2022)
  • Table 111. North America Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 112. North America Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 113. North America Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 114. North America Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 115. United States Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 116. United States Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 117. United States Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 118. United States Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 119. Canada Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 120. Canada Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 121. Canada Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 122. Canada Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 123. Mexico Dry Eye Drugs, by Type USD Million (2017-2022)
  • Table 124. Mexico Dry Eye Drugs, by Application USD Million (2017-2022)
  • Table 125. Mexico Dry Eye Drugs, by Treatment USD Million (2017-2022)
  • Table 126. Mexico Dry Eye Drugs, by Dosage Form USD Million (2017-2022)
  • Table 127. Dry Eye Drugs Sales: by Type(Unit)
  • Table 128. Dry Eye Drugs Sales Artificial Tears , by Region Unit (2017-2022)
  • Table 129. Dry Eye Drugs Sales Anti-inflammatory Drugs , by Region Unit (2017-2022)
  • Table 130. Dry Eye Drugs Sales: by Application(Unit)
  • Table 131. Dry Eye Drugs Sales Hospital Pharmacies , by Region Unit (2017-2022)
  • Table 132. Dry Eye Drugs Sales Drug Stores , by Region Unit (2017-2022)
  • Table 133. Dry Eye Drugs Sales Online Pharmacies , by Region Unit (2017-2022)
  • Table 134. Dry Eye Drugs Sales: by Treatment(Unit)
  • Table 135. Dry Eye Drugs Sales Topical Cyclosporine A Eye Drops , by Region Unit (2017-2022)
  • Table 136. Dry Eye Drugs Sales Lifitegrast , by Region Unit (2017-2022)
  • Table 137. Dry Eye Drugs Sales Artificial Teardrops and Ointments , by Region Unit (2017-2022)
  • Table 138. Dry Eye Drugs Sales Temporary Punctal Occlusion , by Region Unit (2017-2022)
  • Table 139. Dry Eye Drugs Sales Permanent Punctal Occlusion , by Region Unit (2017-2022)
  • Table 140. Dry Eye Drugs Sales Autologous Serum Drops , by Region Unit (2017-2022)
  • Table 141. Dry Eye Drugs Sales: by Dosage Form(Unit)
  • Table 142. Dry Eye Drugs Sales Eye Drops , by Region Unit (2017-2022)
  • Table 143. Dry Eye Drugs Sales Eye Solutions , by Region Unit (2017-2022)
  • Table 144. South America Dry Eye Drugs Sales, by Country Unit (2017-2022)
  • Table 145. South America Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 146. South America Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 147. South America Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 148. South America Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 149. Brazil Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 150. Brazil Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 151. Brazil Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 152. Brazil Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 153. Argentina Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 154. Argentina Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 155. Argentina Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 156. Argentina Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 157. Rest of South America Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 158. Rest of South America Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 159. Rest of South America Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 160. Rest of South America Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 161. Asia Pacific Dry Eye Drugs Sales, by Country Unit (2017-2022)
  • Table 162. Asia Pacific Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 163. Asia Pacific Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 164. Asia Pacific Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 165. Asia Pacific Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 166. China Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 167. China Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 168. China Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 169. China Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 170. Japan Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 171. Japan Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 172. Japan Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 173. Japan Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 174. India Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 175. India Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 176. India Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 177. India Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 178. South Korea Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 179. South Korea Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 180. South Korea Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 181. South Korea Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 182. Taiwan Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 183. Taiwan Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 184. Taiwan Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 185. Taiwan Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 186. Australia Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 187. Australia Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 188. Australia Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 189. Australia Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 190. Rest of Asia-Pacific Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 191. Rest of Asia-Pacific Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 192. Rest of Asia-Pacific Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 193. Rest of Asia-Pacific Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 194. Europe Dry Eye Drugs Sales, by Country Unit (2017-2022)
  • Table 195. Europe Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 196. Europe Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 197. Europe Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 198. Europe Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 199. Germany Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 200. Germany Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 201. Germany Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 202. Germany Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 203. France Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 204. France Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 205. France Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 206. France Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 207. Italy Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 208. Italy Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 209. Italy Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 210. Italy Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 211. United Kingdom Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 212. United Kingdom Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 213. United Kingdom Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 214. United Kingdom Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 215. Netherlands Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 216. Netherlands Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 217. Netherlands Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 218. Netherlands Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 219. Rest of Europe Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 220. Rest of Europe Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 221. Rest of Europe Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 222. Rest of Europe Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 223. MEA Dry Eye Drugs Sales, by Country Unit (2017-2022)
  • Table 224. MEA Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 225. MEA Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 226. MEA Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 227. MEA Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 228. Middle East Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 229. Middle East Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 230. Middle East Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 231. Middle East Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 232. Africa Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 233. Africa Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 234. Africa Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 235. Africa Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 236. North America Dry Eye Drugs Sales, by Country Unit (2017-2022)
  • Table 237. North America Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 238. North America Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 239. North America Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 240. North America Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 241. United States Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 242. United States Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 243. United States Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 244. United States Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 245. Canada Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 246. Canada Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 247. Canada Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 248. Canada Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 249. Mexico Dry Eye Drugs Sales, by Type Unit (2017-2022)
  • Table 250. Mexico Dry Eye Drugs Sales, by Application Unit (2017-2022)
  • Table 251. Mexico Dry Eye Drugs Sales, by Treatment Unit (2017-2022)
  • Table 252. Mexico Dry Eye Drugs Sales, by Dosage Form Unit (2017-2022)
  • Table 253. Dry Eye Drugs: by Type(USD/Units)
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Dry Eye Drugs: by Type(USD Million)
  • Table 264. Dry Eye Drugs Artificial Tears , by Region USD Million (2023-2028)
  • Table 265. Dry Eye Drugs Anti-inflammatory Drugs , by Region USD Million (2023-2028)
  • Table 266. Dry Eye Drugs: by Application(USD Million)
  • Table 267. Dry Eye Drugs Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 268. Dry Eye Drugs Drug Stores , by Region USD Million (2023-2028)
  • Table 269. Dry Eye Drugs Online Pharmacies , by Region USD Million (2023-2028)
  • Table 270. Dry Eye Drugs: by Treatment(USD Million)
  • Table 271. Dry Eye Drugs Topical Cyclosporine A Eye Drops , by Region USD Million (2023-2028)
  • Table 272. Dry Eye Drugs Lifitegrast , by Region USD Million (2023-2028)
  • Table 273. Dry Eye Drugs Artificial Teardrops and Ointments , by Region USD Million (2023-2028)
  • Table 274. Dry Eye Drugs Temporary Punctal Occlusion , by Region USD Million (2023-2028)
  • Table 275. Dry Eye Drugs Permanent Punctal Occlusion , by Region USD Million (2023-2028)
  • Table 276. Dry Eye Drugs Autologous Serum Drops , by Region USD Million (2023-2028)
  • Table 277. Dry Eye Drugs: by Dosage Form(USD Million)
  • Table 278. Dry Eye Drugs Eye Drops , by Region USD Million (2023-2028)
  • Table 279. Dry Eye Drugs Eye Solutions , by Region USD Million (2023-2028)
  • Table 280. South America Dry Eye Drugs, by Country USD Million (2023-2028)
  • Table 281. South America Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 282. South America Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 283. South America Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 284. South America Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 285. Brazil Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 286. Brazil Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 287. Brazil Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 288. Brazil Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 289. Argentina Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 290. Argentina Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 291. Argentina Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 292. Argentina Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 293. Rest of South America Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 294. Rest of South America Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 295. Rest of South America Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 296. Rest of South America Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 297. Asia Pacific Dry Eye Drugs, by Country USD Million (2023-2028)
  • Table 298. Asia Pacific Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 299. Asia Pacific Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 300. Asia Pacific Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 301. Asia Pacific Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 302. China Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 303. China Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 304. China Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 305. China Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 306. Japan Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 307. Japan Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 308. Japan Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 309. Japan Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 310. India Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 311. India Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 312. India Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 313. India Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 314. South Korea Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 315. South Korea Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 316. South Korea Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 317. South Korea Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 318. Taiwan Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 319. Taiwan Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 320. Taiwan Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 321. Taiwan Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 322. Australia Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 323. Australia Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 324. Australia Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 325. Australia Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 326. Rest of Asia-Pacific Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 327. Rest of Asia-Pacific Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 328. Rest of Asia-Pacific Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 329. Rest of Asia-Pacific Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 330. Europe Dry Eye Drugs, by Country USD Million (2023-2028)
  • Table 331. Europe Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 332. Europe Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 333. Europe Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 334. Europe Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 335. Germany Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 336. Germany Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 337. Germany Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 338. Germany Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 339. France Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 340. France Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 341. France Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 342. France Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 343. Italy Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 344. Italy Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 345. Italy Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 346. Italy Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 347. United Kingdom Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 348. United Kingdom Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 349. United Kingdom Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 350. United Kingdom Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 351. Netherlands Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 352. Netherlands Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 353. Netherlands Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 354. Netherlands Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 355. Rest of Europe Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 356. Rest of Europe Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 357. Rest of Europe Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 358. Rest of Europe Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 359. MEA Dry Eye Drugs, by Country USD Million (2023-2028)
  • Table 360. MEA Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 361. MEA Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 362. MEA Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 363. MEA Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 364. Middle East Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 365. Middle East Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 366. Middle East Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 367. Middle East Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 368. Africa Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 369. Africa Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 370. Africa Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 371. Africa Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 372. North America Dry Eye Drugs, by Country USD Million (2023-2028)
  • Table 373. North America Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 374. North America Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 375. North America Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 376. North America Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 377. United States Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 378. United States Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 379. United States Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 380. United States Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 381. Canada Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 382. Canada Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 383. Canada Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 384. Canada Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 385. Mexico Dry Eye Drugs, by Type USD Million (2023-2028)
  • Table 386. Mexico Dry Eye Drugs, by Application USD Million (2023-2028)
  • Table 387. Mexico Dry Eye Drugs, by Treatment USD Million (2023-2028)
  • Table 388. Mexico Dry Eye Drugs, by Dosage Form USD Million (2023-2028)
  • Table 389. Dry Eye Drugs Sales: by Type(Unit)
  • Table 390. Dry Eye Drugs Sales Artificial Tears , by Region Unit (2023-2028)
  • Table 391. Dry Eye Drugs Sales Anti-inflammatory Drugs , by Region Unit (2023-2028)
  • Table 392. Dry Eye Drugs Sales: by Application(Unit)
  • Table 393. Dry Eye Drugs Sales Hospital Pharmacies , by Region Unit (2023-2028)
  • Table 394. Dry Eye Drugs Sales Drug Stores , by Region Unit (2023-2028)
  • Table 395. Dry Eye Drugs Sales Online Pharmacies , by Region Unit (2023-2028)
  • Table 396. Dry Eye Drugs Sales: by Treatment(Unit)
  • Table 397. Dry Eye Drugs Sales Topical Cyclosporine A Eye Drops , by Region Unit (2023-2028)
  • Table 398. Dry Eye Drugs Sales Lifitegrast , by Region Unit (2023-2028)
  • Table 399. Dry Eye Drugs Sales Artificial Teardrops and Ointments , by Region Unit (2023-2028)
  • Table 400. Dry Eye Drugs Sales Temporary Punctal Occlusion , by Region Unit (2023-2028)
  • Table 401. Dry Eye Drugs Sales Permanent Punctal Occlusion , by Region Unit (2023-2028)
  • Table 402. Dry Eye Drugs Sales Autologous Serum Drops , by Region Unit (2023-2028)
  • Table 403. Dry Eye Drugs Sales: by Dosage Form(Unit)
  • Table 404. Dry Eye Drugs Sales Eye Drops , by Region Unit (2023-2028)
  • Table 405. Dry Eye Drugs Sales Eye Solutions , by Region Unit (2023-2028)
  • Table 406. South America Dry Eye Drugs Sales, by Country Unit (2023-2028)
  • Table 407. South America Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 408. South America Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 409. South America Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 410. South America Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 411. Brazil Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 412. Brazil Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 413. Brazil Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 414. Brazil Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 415. Argentina Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 416. Argentina Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 417. Argentina Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 418. Argentina Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 419. Rest of South America Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 420. Rest of South America Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 421. Rest of South America Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 422. Rest of South America Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 423. Asia Pacific Dry Eye Drugs Sales, by Country Unit (2023-2028)
  • Table 424. Asia Pacific Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 425. Asia Pacific Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 426. Asia Pacific Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 427. Asia Pacific Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 428. China Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 429. China Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 430. China Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 431. China Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 432. Japan Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 433. Japan Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 434. Japan Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 435. Japan Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 436. India Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 437. India Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 438. India Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 439. India Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 440. South Korea Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 441. South Korea Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 442. South Korea Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 443. South Korea Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 444. Taiwan Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 445. Taiwan Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 446. Taiwan Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 447. Taiwan Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 448. Australia Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 449. Australia Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 450. Australia Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 451. Australia Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 452. Rest of Asia-Pacific Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 453. Rest of Asia-Pacific Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 454. Rest of Asia-Pacific Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 455. Rest of Asia-Pacific Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 456. Europe Dry Eye Drugs Sales, by Country Unit (2023-2028)
  • Table 457. Europe Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 458. Europe Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 459. Europe Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 460. Europe Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 461. Germany Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 462. Germany Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 463. Germany Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 464. Germany Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 465. France Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 466. France Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 467. France Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 468. France Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 469. Italy Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 470. Italy Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 471. Italy Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 472. Italy Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 473. United Kingdom Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 474. United Kingdom Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 475. United Kingdom Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 476. United Kingdom Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 477. Netherlands Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 478. Netherlands Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 479. Netherlands Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 480. Netherlands Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 481. Rest of Europe Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 482. Rest of Europe Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 483. Rest of Europe Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 484. Rest of Europe Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 485. MEA Dry Eye Drugs Sales, by Country Unit (2023-2028)
  • Table 486. MEA Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 487. MEA Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 488. MEA Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 489. MEA Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 490. Middle East Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 491. Middle East Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 492. Middle East Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 493. Middle East Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 494. Africa Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 495. Africa Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 496. Africa Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 497. Africa Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 498. North America Dry Eye Drugs Sales, by Country Unit (2023-2028)
  • Table 499. North America Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 500. North America Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 501. North America Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 502. North America Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 503. United States Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 504. United States Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 505. United States Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 506. United States Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 507. Canada Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 508. Canada Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 509. Canada Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 510. Canada Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 511. Mexico Dry Eye Drugs Sales, by Type Unit (2023-2028)
  • Table 512. Mexico Dry Eye Drugs Sales, by Application Unit (2023-2028)
  • Table 513. Mexico Dry Eye Drugs Sales, by Treatment Unit (2023-2028)
  • Table 514. Mexico Dry Eye Drugs Sales, by Dosage Form Unit (2023-2028)
  • Table 515. Dry Eye Drugs: by Type(USD/Units)
  • Table 516. Research Programs/Design for This Report
  • Table 517. Key Data Information from Secondary Sources
  • Table 518. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dry Eye Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Dry Eye Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Dry Eye Drugs: by Treatment USD Million (2017-2022)
  • Figure 7. Global Dry Eye Drugs: by Dosage Form USD Million (2017-2022)
  • Figure 8. South America Dry Eye Drugs Share (%), by Country
  • Figure 9. Asia Pacific Dry Eye Drugs Share (%), by Country
  • Figure 10. Europe Dry Eye Drugs Share (%), by Country
  • Figure 11. MEA Dry Eye Drugs Share (%), by Country
  • Figure 12. North America Dry Eye Drugs Share (%), by Country
  • Figure 13. Global Dry Eye Drugs: by Type Unit (2017-2022)
  • Figure 14. Global Dry Eye Drugs: by Application Unit (2017-2022)
  • Figure 15. Global Dry Eye Drugs: by Treatment Unit (2017-2022)
  • Figure 16. Global Dry Eye Drugs: by Dosage Form Unit (2017-2022)
  • Figure 17. South America Dry Eye Drugs Share (%), by Country
  • Figure 18. Asia Pacific Dry Eye Drugs Share (%), by Country
  • Figure 19. Europe Dry Eye Drugs Share (%), by Country
  • Figure 20. MEA Dry Eye Drugs Share (%), by Country
  • Figure 21. North America Dry Eye Drugs Share (%), by Country
  • Figure 22. Global Dry Eye Drugs: by Type USD/Units (2017-2022)
  • Figure 23. Global Dry Eye Drugs share by Players 2022 (%)
  • Figure 24. Global Dry Eye Drugs share by Players (Top 3) 2022(%)
  • Figure 25. Global Dry Eye Drugs share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. Allergan plc (Ireland) Revenue: by Geography 2022
  • Figure 29. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 31. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2022
  • Figure 33. Santen Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Santen Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2022
  • Figure 35. Shire Plc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Shire Plc (United States) Revenue: by Geography 2022
  • Figure 37. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 39. United Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. United Laboratories, Inc. (United States) Revenue: by Geography 2022
  • Figure 41. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 42. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 43. Senju Pharmaceutical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 44. Senju Pharmaceutical Co. Ltd. (Japan) Revenue: by Geography 2022
  • Figure 45. Global Dry Eye Drugs: by Type USD Million (2023-2028)
  • Figure 46. Global Dry Eye Drugs: by Application USD Million (2023-2028)
  • Figure 47. Global Dry Eye Drugs: by Treatment USD Million (2023-2028)
  • Figure 48. Global Dry Eye Drugs: by Dosage Form USD Million (2023-2028)
  • Figure 49. South America Dry Eye Drugs Share (%), by Country
  • Figure 50. Asia Pacific Dry Eye Drugs Share (%), by Country
  • Figure 51. Europe Dry Eye Drugs Share (%), by Country
  • Figure 52. MEA Dry Eye Drugs Share (%), by Country
  • Figure 53. North America Dry Eye Drugs Share (%), by Country
  • Figure 54. Global Dry Eye Drugs: by Type Unit (2023-2028)
  • Figure 55. Global Dry Eye Drugs: by Application Unit (2023-2028)
  • Figure 56. Global Dry Eye Drugs: by Treatment Unit (2023-2028)
  • Figure 57. Global Dry Eye Drugs: by Dosage Form Unit (2023-2028)
  • Figure 58. South America Dry Eye Drugs Share (%), by Country
  • Figure 59. Asia Pacific Dry Eye Drugs Share (%), by Country
  • Figure 60. Europe Dry Eye Drugs Share (%), by Country
  • Figure 61. MEA Dry Eye Drugs Share (%), by Country
  • Figure 62. North America Dry Eye Drugs Share (%), by Country
  • Figure 63. Global Dry Eye Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Allergan plc (Ireland)
  • Novartis International AG (Switzerland)
  • Bausch Health Companies Inc. (Canada)
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Shire Plc (United States)
  • Johnson & Johnson (United States)
  • United Laboratories, Inc. (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Senju Pharmaceutical Co. Ltd. (Japan)
Additional players considered in the study are as follows:
Chongqing Jianfeng Industrial Group Co., Ltd (China) , Kala Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 224 Pages 63 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dry Eye Drugs Quantitative research analysis
Global Dry Eye Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Dry Eye Drugs Market are by type [Artificial Tears and Anti-inflammatory Drugs], by end use application [Hospital Pharmacies, Drug Stores and Online Pharmacies].
The Dry Eye Drugs Market is gaining popularity and expected to see strong valuation by 2028.
  • Increase in the Prevalence of Dry Eye Syndrome
  • A Rising Awareness of Eye Care
  • Increase in Awareness among the Population about Dry Eye Disease

Know More About Global Dry Eye Drugs Report?

Have a Query? Click Here

Other Related Reports

Optic Neuropathy Drug Comprehensive Study by Type (BA-240, IWP-953, LM-22A4, Others), Application (Hospitals, Ophthalmic clinics, Ambulatory Surgical Centres), Distribution Channel (Prescription Drug...
$ 3350
Sexual Enhancement Supplements Comprehensive Study by Type (Male Sexual Enhancement Supplements, Female Sexual Enhancement Supplements), Application (Individual Use, Commercial Use), Distribution Cha...
$ 3750
Fetal Bovine Serum Comprehensive Study by Application (Drug Discovery, Cell Culture Media, Vitro Fertilization, Human and Animal Vaccine production, Diagnostics, Others), End-Users (Research and Acad...
$ 3450
Pharma Track and Trace Solutions Comprehensive Study by Application (Serialization, Aggregations, Reporting), By components (Software, Services), By Technology (Barcodes, RFID), End User (BioPharma, ...
$ 3350
Melatonin Comprehensive Study by Type (Pharmaceutical Grade, Food Grade), Application (Dietary Supplements, Medical, Others), Form (Pill, Capsule, Chewable, Liquid, Gummy), Distribution Channel (Offl...
$ 3500
Opioids Drug Comprehensive Study by Type (Morphine, Codeine, Fentanyl, Meperidine, Methadone, Others), Application (Pain Management, Cough Supression, Diarrhea Suppresion, Others), Receptor Binding (...
$ 3350